ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2021
Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.Alzheimer's research & therapy · 2022Pooled it
- Value of Knowing: Health-Related Behavior Changes following Amyloid PET Results Disclosure in Mild Cognitive Impairment.The journal of prevention of Alzheimer's disease · 2024Trial
- Article
- Just Semantics? How Diagnostic Criteria Influence Physician-Patient Narratives in Alzheimer's Disease.Neuro-degenerative diseases · 2026Article
- No cognitive or psychological impact from returning research Alzheimer disease biomarkers: A delayed-start, noninferiority, randomized clinical trial.medRxiv : the preprint server for health sciences · 2026Article
- Willingness and barriers to blood-based biomarker testing of Alzheimer's disease in the general population in the Czech Republic.Alzheimer's research & therapy · 2026Article
- New Alzheimer's disease diagnostics and psychological clinical perspectives.Frontiers in psychology · 2026Article
- Preferences of research participants with experience receiving individual results for future return of results.Journal of clinical and translational science · 2026Article
- Clinical definition, biological characterization, and detection guidelines of subjective cognitive decline due to Alzheimer's disease and related dementia: A position paper from ISTAART SCD PIA.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges.The journal of prevention of Alzheimer's disease · 2025Review
- The duality of disease: the Alzheimer's disease dilemma through the lens of nosos and asthenia.Brain : a journal of neurology · 2025Article
- Comparison of amyloid PET acquired through standardized and unstandardized protocols.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Association between Trust of Researchers and Willingness to Participate in Alzheimer's Disease Biomarker Research.Alzheimer's & dementia. Behavior & socioeconomics of aging · 2025Article
- Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies.AJNR. American journal of neuroradiology · 2025Review
- Return of research results across the Alzheimer's Disease Research Centers network.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Genetic and biomarker disclosure process in a memory and aging study.Journal of Alzheimer's disease : JAD · 2025Article
- The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Communicating the risk of dementia: a scoping review.BMJ neurology open · 2025Article
- Article
- Paving the way for Alzheimer's disease blood-based biomarkers in primary care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Disclosure of personal disease-related information to asymptomatic adults has been debated over the last century in medicine and research. Recently, Alzheimer's disease (AD) has been conceptualized as a continuum that begins with a "preclinical" stage in which biomarkers are present in the absence of cognitive impairment. Studies have begun assessing the safety, psychological, and behavioral effects of disclosing both AD-related genetic and biomarker information to cognitively unimpaired older adults. Yet, debate continues over the appropriate circumstances and methods for returning such information. This article outlines concerns with and rationale for AD biomarker disclosure and summarizes findings from prior studies. Overall, this article aims to describe and respond to key questions concerning disclosure of amyloid positron emission tomography scan results to asymptomatic adults in a research setting. Moving forward, such conditions are important to consider as interventions target the preclinical phase of AD and normalize disclosing biomarker information to cognitively unimpaired persons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.